Kim Tang

Executive Director of Research

Kim Tang brings over three decades of experience leading and advancing drug discovery programs from preclinical target identification through early clinical development. His expertise spans multiple disease areas and target classes, with a proven track record in novel target identification, validation, pharmacology, translational biology and drug candidate optimization.

Prior to his current role, Mr. Tang served as Executive Director of Platform Pharmacology at Dyne Therapeutics, where he led efforts to characterize and optimize targeted therapeutics for rare muscle diseases. Before joining Dyne, Mr. Tang held scientific leadership roles at Axial Biotherapeutics, Ironwood Pharmaceuticals, Cubist Pharmaceuticals, Anchor Therapeutics and Pfizer. Across his career Mr. Tang has led research programs that delivered multiple new clinical candidates that successfully demonstrated clinical efficacy, leading to the launch of one transformational new medicine.

Mr. Tang obtained a BSc in pharmacology from the University of Southampton.